Notify me when Bain Capital Life Sciences Opportunities III, LP files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| CABA | CABALETTA BIO, INC. | Common Stock, $0.00001 par value per share | 10% | $15,483,400 | 9,677,125 | Bain Capital Life Sciences Opportunities III, LP | 30 Jun 2025 | ||
| KYTX | KYVERNA THERAPEUTICS, INC. | Common Stock, $0.00001 par value per share | 5.4% | $25,595,300 | 3,110,000 | Bain Capital Life Sciences Opportunities III, LP | 31 Dec 2025 | ||
| IPSC | CENTURY THERAPEUTICS, INC. | Common Stock, $0.0001 par value per share | 4.1% | $1,762,227 | 3,538,609 | Bain Capital Life Sciences Opportunities III, LP | 30 Sep 2025 | ||
| IRON | Disc Medicine, Inc. | Common Stock, $0.0001 par value per share | 3.3% | $46,372,025 | 983,500 | Bain Capital Life Sciences Opportunities III, LP | 31 Dec 2024 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|